Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 985620, 15 pages
http://dx.doi.org/10.1155/2012/985620
Review Article

Breast Cancer Chemoprevention: Old and New Approaches

Division of Cancer Prevention and Genetics, European Institute of Oncology, 20141 Milan, Italy

Received 11 April 2012; Accepted 10 May 2012

Academic Editor: Su S. Chen

Copyright © 2012 Massimiliano Cazzaniga and Bernardo Bonanni. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Smigal, A. Jemal, E. Ward et al., “Trends in breast cancer by race and ethnicity: update 2006,” Ca-A Cancer Journal for Clinicians, vol. 56, no. 3, pp. 168–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Youlden, S. M. Cramb, N. A. M. Dunn, J. M. Muller, C. M. Pyke, and P. D. Baade, “The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality,” Cancer Epidemiology, vol. 36, no. 3, pp. 237–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. T. Tirona, R. Sehgal, and O. Ballester, “Prevention of breast cancer (Part I): epidemiology, risk factors, and risk assessment tools,” Cancer Investigation, vol. 28, no. 7, pp. 743–750, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. B. Sporn, “Approaches to prevention of epithelial cancer during the preneoplastic period,” Cancer Research, vol. 36, no. 7, pp. 2699–2702, 1976. View at Google Scholar · View at Scopus
  5. J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon et al., “Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development: recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia,” Clinical Cancer Research, vol. 8, no. 2, pp. 314–346, 2002. View at Google Scholar · View at Scopus
  6. B. J. M. Braakhuis, M. P. Tabor, J. A. Kummer, C. R. Leemans, and R. H. Brakenhoff, “A genetic explanation of slaughter's concept of field cancerization: evidence and clinical implications,” Cancer Research, vol. 63, no. 8, pp. 1727–1730, 2003. View at Google Scholar · View at Scopus
  7. M. D. Althuis, J. H. Fergenbaum, M. Garcia-Closas, L. A. Brinton, M. P. Madigan, and M. E. Sherman, “Etiology of hormone receptor-defined breast cancer: a systematic review of the literature,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 10, pp. 1558–1568, 2004. View at Google Scholar · View at Scopus
  8. V. Pelekanou and G. Leclercq, “Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis,” International Journal of Developmental Biology, vol. 55, no. 7-9, pp. 869–878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. E. K. Shanle and W. Xu, “Selectively targeting estrogen receptors for cancer treatment,” Advanced Drug Delivery Reviews, vol. 62, no. 13, pp. 1265–1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. V. C. Jordan, “Selective estrogen receptor modulation: a personal perspective,” Cancer Research, vol. 61, no. 15, pp. 5683–5687, 2001. View at Google Scholar · View at Scopus
  11. Early Breast Cancer Trialists’ Collaborative Groups, “Tamoxifen for early breast cancer: an overview of the randomized trials,” The Lancet, vol. 351, pp. 1451–1467, 1998. View at Google Scholar
  12. B. Fisher, J. P. Costantino, D. L. Wickerham et al., “Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study,” Journal of the National Cancer Institute, vol. 90, no. 18, pp. 1371–1388, 1998. View at Google Scholar · View at Scopus
  13. M. C. King, S. Wieand, K. Hale et al., “Tamoxifen and breast cancer incidence among women with inherited mutations in brca1 and brca2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial,” Journal of the American Medical Association, vol. 286, no. 18, pp. 2251–2256, 2001. View at Google Scholar · View at Scopus
  14. J. Cuzick, “First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial,” The Lancet, vol. 360, no. 9336, pp. 817–824, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Cuzick, T. Powles, U. Veronesi et al., “Overview of the main outcomes in breast-cancer prevention trials,” The Lancet, vol. 361, no. 9354, pp. 296–300, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Decensi, B. Bonanni, A. Guerrieri-Gonzaga et al., “Biologic activity of tamoxifen at low doses in healthy women,” Journal of the National Cancer Institute, vol. 90, no. 19, pp. 1461–1467, 1998. View at Google Scholar · View at Scopus
  17. S. R. D. Johnston, B. P. Haynes, N. P. M. Sacks et al., “Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer,” Breast Cancer Research and Treatment, vol. 28, no. 3, pp. 241–250, 1993. View at Google Scholar · View at Scopus
  18. A. Guerrieri-Gonzaga, L. Baglietto, H. Johansson et al., “Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 9, pp. 967–970, 2001. View at Google Scholar · View at Scopus
  19. A. Decensi, C. Robertson, G. Viale et al., “A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers,” Journal of the National Cancer Institute, vol. 95, no. 11, pp. 779–790, 2003. View at Google Scholar · View at Scopus
  20. E. Barrett-Connor, L. Mosca, P. Collins et al., “Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women,” New England Journal of Medicine, vol. 355, no. 2, pp. 125–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Martino, J. A. Cauley, E. Barrett-Connor et al., “Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene,” Journal of the National Cancer Institute, vol. 96, pp. 1751–1761, 2004. View at Google Scholar
  22. M. B. Sporn, S. A. Dowsett, J. Mershon, and H. U. Bryant, “Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action,” Clinical Therapeutics, vol. 26, no. 6, pp. 830–840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Cummings, S. Eckert, K. A. Krueger et al., “The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial,” Journal of the American Medical Association, vol. 281, no. 23, pp. 2189–2197, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Ettinger, D. M. Black, B. H. Mitlak et al., “Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial,” Journal of the American Medical Association, vol. 282, no. 7, pp. 637–645, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Cauley, L. Norton, M. E. Lippman et al., “Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial,” Breast Cancer Research and Treatment, vol. 65, no. 2, pp. 125–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of the American Medical Association, vol. 295, no. 23, pp. 2727–2741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Mosca, E. Barrett-Connor, N. K. Wenger et al., “Design and methods of the Raloxifene Use for The Heart (RUTH) study,” American Journal of Cardiology, vol. 88, no. 4, pp. 392–395, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. S. Coates, A. Keshaviah, B. Thürlimann et al., “Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 486–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Coombes, L. Kilburn, C. Snowdon et al., “Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial,” The Lancet, vol. 369, no. 9561, pp. 559–570, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. P. E. Goss, J. N. Ingle, S. Martino et al., “A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,” New England Journal of Medicine, vol. 349, no. 19, pp. 1793–1802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Baum, A. U. Buzdar, J. Cuzick et al., “Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial,” The Lancet, vol. 359, no. 9324, pp. 2131–2139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Howell, J. Cuzick, and M. Baum, “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer,” The Lancet, vol. 365, no. 9453, pp. 60–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. R. C. Coombes, E. Hall, L. J. Gibson et al., “A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,” New England Journal of Medicine, vol. 350, no. 11, pp. 1081–1092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Perez, “Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer,” Annals of Oncology, vol. 18, supplement 8, pp. viii26–viii35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Cuzick, “Aromatase inhibitors for breast cancer prevention,” Journal of Clinical Oncology, vol. 23, no. 8, pp. 1636–1643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. P. E. Goss, K. Strasser-Weippl, M. Brown, R. Santen, J. Ingle, and M. Bissell, “Prevention strategies with aromatase inhibitors,” Clinical Cancer Research, vol. 10, no. 1, pp. 372S–379S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Cuzick, “IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole,” Expert Review of Anticancer Therapy, vol. 8, no. 9, pp. 1377–1385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study,” Journal of the American Medical Association, vol. 295, no. 21, pp. 2492–2502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. R. C. Moon, H. J. Thompson, and P. J. Becci, “N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat,” Cancer Research, vol. 39, no. 4, pp. 1339–1346, 1979. View at Google Scholar · View at Scopus
  40. G. T. Budd, P. C. Adamson, M. Gupta et al., “Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer,” Clinical Cancer Research, vol. 4, no. 3, pp. 635–642, 1998. View at Google Scholar · View at Scopus
  41. A. Decensi, B. Bonanni, L. Baglietto et al., “A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers,” Clinical Cancer Research, vol. 10, no. 13, pp. 4389–4397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Cazzaniga, C. Varricchio, C. Montefrancesco, I. Feroce, and A. Guerrieri-Gonzaga, “Fenretinide (4-HPR): A preventive chance for women at genetic and familial risk?” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 172897, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Veronesi, G. De Palo, E. Marubini et al., “Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer,” Journal of the National Cancer Institute, vol. 91, no. 21, pp. 1847–1856, 1999. View at Google Scholar · View at Scopus
  44. U. Veronesi, L. Mariani, A. Decensi et al., “Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer,” Annals of Oncology, vol. 17, no. 7, pp. 1065–1071, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Wu, H. T. Kim, J. L. Rodriquez et al., “Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 5, pp. 467–474, 2002. View at Google Scholar · View at Scopus
  46. K. Wu, Y. Zhang, X. C. Xu et al., “The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice,” Cancer Research, vol. 62, no. 22, pp. 6376–6380, 2002. View at Google Scholar · View at Scopus
  47. C. Lu, C. Speers, Y. Zhang et al., “Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors,” Journal of the National Cancer Institute, vol. 95, no. 24, pp. 1825–1833, 2003. View at Google Scholar · View at Scopus
  48. K. Imai and A. Takaoka, “Comparing antibody and small-molecule therapies for cancer,” Nature Reviews Cancer, vol. 6, no. 9, pp. 714–727, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Seshadri, F. A. Firgaira, D. J. Horsfall, K. McCaul, V. Setlur, and P. Kitchen, “Clinical significance of HER-2/neu oncogene amplification in primary breast cancer,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1936–1942, 1993. View at Google Scholar · View at Scopus
  50. A. K. Tandon, G. M. Clark, G. C. Chamness, A. Ullrich, and W. L. McGuire, “HER-2/neu oncogene protein and prognosis in breast cancer,” Journal of Clinical Oncology, vol. 7, no. 8, pp. 1120–1128, 1989. View at Google Scholar · View at Scopus
  51. G. Konecny, G. Pauletti, M. Pegram et al., “Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer,” Journal of the National Cancer Institute, vol. 95, no. 2, pp. 142–153, 2003. View at Google Scholar · View at Scopus
  52. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Brufsky, B. Lembersky, K. Schiffman, G. Lieberman, and V. E. Paton, “Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer,” Clinical Breast Cancer, vol. 6, no. 3, pp. 247–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. U. Buzdar, V. Valero, N. K. Ibrahim et al., “Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen,” Clinical Cancer Research, vol. 13, no. 1, pp. 228–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Gianni, W. Eiermann, V. Semiglazov et al., “Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort,” The Lancet, vol. 375, no. 9712, pp. 377–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Baselga, E. A. Perez, T. Pienkowski, and R. Bell, “Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer,” Oncologist, vol. 11, no. 1, pp. 4–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. J. T. Hartmann, M. Haap, H. G. Kopp, and H. P. Lipp, “Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects,” Current Drug Metabolism, vol. 10, no. 5, pp. 470–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Cameron, M. Casey, M. Press et al., “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. U. Lin, L. A. Carey, M. C. Liu et al., “Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 1993–1999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Di Leo, H. L. Gomez, Z. Aziz et al., “Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 34, pp. 5544–5552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. T. E. Strecker, Q. Shen, Y. Zhang et al., “Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice,” Journal of the National Cancer Institute, vol. 101, no. 2, pp. 107–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. P. M. Harari, “Epidermal growth factor receptor inhibition strategies in oncology,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 689–708, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Ciardiello and G. Tortora, “A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor,” Clinical Cancer Research, vol. 7, no. 10, pp. 2958–2970, 2001. View at Google Scholar · View at Scopus
  64. A. Agrawal, E. Gutteridge, J. M. W. Gee, R. I. Nicholson, and J. F. R. Robertson, “Overview of tyrosine kinase inhibitors in clinical breast cancer,” Endocrine-Related Cancer, vol. 12, no. 1, pp. S135–S144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. M. N. Dickler, H. S. Rugo, C. Eberle et al., “A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer,” Clinical Cancer Research, vol. 14, no. 23, pp. 7878–7883, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. K. C. Chan, W. F. Knox, J. M. Gee et al., “Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast,” Cancer Research, vol. 62, no. 1, pp. 122–128, 2002. View at Google Scholar · View at Scopus
  67. E. Half, X. M. Tang, K. Gwyn, A. Sahin, K. Wathen, and F. A. Sinicrope, “Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ,” Cancer Research, vol. 62, no. 6, pp. 1676–1681, 2002. View at Google Scholar · View at Scopus
  68. M. J. Thun, S. Jane Henley, and C. Patrono, “Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues,” Journal of the National Cancer Institute, vol. 94, no. 4, pp. 252–266, 2002. View at Google Scholar · View at Scopus
  69. J. Cuzick, F. Otto, J. A. Baron et al., “Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement,” The Lancet Oncology, vol. 10, no. 5, pp. 501–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Schottenfeld and J. Beebe-Dimmer, “Chronic inflammation: a common and important factor in the pathogenesis of neoplasia,” Ca-A Cancer Journal for Clinicians, vol. 56, no. 2, pp. 69–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Shim, M. L. Gauthier, D. Sudilovsky et al., “Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium,” Cancer Research, vol. 63, no. 10, pp. 2347–2350, 2003. View at Google Scholar · View at Scopus
  72. S. A. Khuder and A. B. Mutgi, “Breast cancer and NSAID use: a meta-analysis,” British Journal of Cancer, vol. 84, no. 9, pp. 1188–1192, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. B. Takkouche, C. Regueira-Méndez, and M. Etminan, “Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis,” Journal of the National Cancer Institute, vol. 100, no. 20, pp. 1439–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. R. E. Harris, G. A. Alshafie, H. Abou-Issa, and K. Seibert, “Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor,” Cancer Research, vol. 60, no. 8, pp. 2101–2103, 2000. View at Google Scholar · View at Scopus
  75. S. Nakatsugi, T. Ohta, T. Kawamori et al., “Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats,” Japanese Journal of Cancer Research, vol. 91, no. 9, pp. 886–892, 2000. View at Google Scholar · View at Scopus
  76. R. G. G. Russell, “Bisphosphonates: the first 40 years,” Bone, vol. 49, no. 1, pp. 2–19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. G. A. Rodan and H. A. Fleisch, “Bisphosphonates: mechanisms of action,” Journal of Clinical Investigation, vol. 97, no. 12, pp. 2692–2696, 1996. View at Google Scholar · View at Scopus
  78. A. Brufsky, W. G. Harker, J. T. Beck et al., “Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 829–836, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. T. J. Hall and M. Schaueblin, “A pharmacological assessment of the mammalian osteoclast vacuolar H+-ATPase,” Bone and Mineral, vol. 27, no. 2, pp. 159–166, 1994. View at Google Scholar · View at Scopus
  80. G. Rennert, M. Pinchev, and H. S. Rennert, “Use of bisphosphonates and risk of postmenopausal breast cancer,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3577–3581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. R. T. Chlebowski, Z. Chen, J. A. Cauley et al., “Oral bisphosphonate use and breast cancer incidence in postmenopausal women,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3582–3590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. C. Amé, C. Spenlehauer, and G. De Murcia, “The PARP superfamily,” BioEssays, vol. 26, no. 8, pp. 882–893, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. F. Dantzer, J. C. Amé, V. Schreiber, J. Nakamura, J. Ménissier-de Murcia, and G. de Murcia, “Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair,” Methods in Enzymology, vol. 409, pp. 493–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. J. C. Amé, V. Rolli, V. Schreiber et al., “PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase,” Journal of Biological Chemistry, vol. 274, no. 25, pp. 17860–17868, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Peralta-Leal, J. M. Rodríguez-Vargas, R. Aguilar-Quesada et al., “PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases,” Free Radical Biology and Medicine, vol. 47, no. 1, pp. 13–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Calvert and A. Azzariti, “The clinical development of inhibitors of poly(ADP-ribose) polymerase,” Annals of Oncology, vol. 22, no. 1, pp. i53–i59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. F. L. Rehman, C. J. Lord, and A. Ashworth, “Synthetic lethal approaches to breast cancer therapy,” Nature Reviews Clinical Oncology, vol. 7, no. 12, pp. 718–724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. D. Iglehart and D. P. Silver, “Synthetic lethality—a new direction in cancer-drug development,” New England Journal of Medicine, vol. 361, no. 2, pp. 189–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Evers, R. Drost, E. Schut et al., “Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin,” Clinical Cancer Research, vol. 14, no. 12, pp. 3916–3925, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. H. E. Bryant, N. Schultz, H. D. Thomas et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase,” Nature, vol. 434, no. 7035, pp. 913–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. J. O'Shaughnessy, C. Osborne, J. E. Pippen et al., “Iniparib plus chemotherapy in metastatic triple-negative breast cancer,” New England Journal of Medicine, vol. 364, no. 3, pp. 205–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. P. C. Fong, D. S. Boss, T. A. Yap et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers,” New England Journal of Medicine, vol. 361, no. 2, pp. 123–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. F. Xue and K. B. Michels, “Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence.,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s823–835, 2007. View at Google Scholar · View at Scopus
  94. I. R. Hsu, S. P. Kim, M. Kabir, and R. N. Bergman, “Metabolic syndrome, hyperinsulinemia, and cancer.,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s867–871, 2007. View at Google Scholar · View at Scopus
  95. P. J. Goodwin, M. Ennis, K. I. Pritchard et al., “Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study,” Journal of Clinical Oncology, vol. 20, no. 1, pp. 42–51, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. P. Pasanisi, F. Berrino, M. De Petris, E. Venturelli, A. Mastroianni, and S. Panico, “Metabolic syndrome as a prognostic factor for breast cancer recurrences,” International Journal of Cancer, vol. 119, no. 1, pp. 236–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. M. L. Irwin, A. McTiernan, L. Bernstein et al., “Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 12, pp. 2881–2888, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. M. J. Gunter, D. R. Hoover, H. Yu et al., “Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women,” Journal of the National Cancer Institute, vol. 101, no. 1, pp. 48–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, “Insulin-like growth factors and neoplasia,” Nature Reviews Cancer, vol. 4, no. 7, pp. 505–518, 2004. View at Google Scholar · View at Scopus
  100. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri, “Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease,” Endocrine Reviews, vol. 30, no. 6, pp. 586–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. I. Wolf, S. Sadetzki, R. Catane, A. Karasik, and B. Kaufman, “Diabetes mellitus and breast cancer,” The Lancet Oncology, vol. 6, no. 2, pp. 103–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Pollak, “Insulin and insulin-like growth factor signalling in neoplasia,” Nature Reviews Cancer, vol. 8, no. 12, pp. 915–928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin,” Diabetes Care, vol. 29, no. 2, pp. 254–258, 2006. View at Google Scholar · View at Scopus
  105. A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 3, no. 11, pp. 1451–1461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. I. B. Sahra, K. Laurent, A. Loubat et al., “The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level,” Oncogene, vol. 27, no. 25, pp. 3576–3586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, “Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells,” Cancer Research, vol. 66, no. 21, pp. 10269–10273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. K. N. Phoenix, F. Vumbaca, and K. P. Claffey, “Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model,” Breast Cancer Research and Treatment, vol. 113, no. 1, pp. 101–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Cazzaniga, B. Bonanni, A. Guerrieri-Gonzaga, and A. Decensi, “Is it time to test metformin in breast cancer clinical trials?” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 701–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. F. Chen, V. Castranova, and X. Shi, “New insights into the role of nuclear factor-κB in cell growth regulation,” American Journal of Pathology, vol. 159, no. 2, pp. 387–397, 2001. View at Google Scholar · View at Scopus
  111. M. J. Lenardo and D. Baltimore, “NK-κB: a pleiotropic mediator of inducible and tissue-specific gene control,” Cell, vol. 58, no. 2, pp. 227–229, 1989. View at Google Scholar · View at Scopus
  112. M. Karin, “Nuclear factor-κB in cancer development and progression,” Nature, vol. 441, no. 7092, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Karin, “NF-κB and cancer: mechanisms and targets,” Molecular Carcinogenesis, vol. 45, no. 6, pp. 355–361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Bowie and L. A. J. O'Neill, “Oxidative stress and nuclear factor-κB activation: a reassessment of the evidence in the light of recent discoveries,” Biochemical Pharmacology, vol. 59, no. 1, pp. 13–23, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. M. B. Toledano and W. J. Leonard, “Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 10, pp. 4328–4332, 1991. View at Google Scholar · View at Scopus
  116. H. L. Pahl, “Activators and target genes of Rel/NF-κB transcription factors,” Oncogene, vol. 18, no. 49, pp. 6853–6866, 1999. View at Google Scholar · View at Scopus
  117. N. Ahmad, S. Gupta, and H. Mukhtar, “Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells,” Archives of Biochemistry and Biophysics, vol. 376, no. 2, pp. 338–346, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. A. C. Bharti, N. Donato, S. Singh, and B. B. Aggarwal, “Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis,” Blood, vol. 101, no. 3, pp. 1053–1062, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. S. R. Chinni, Y. Li, S. Upadhyay, P. K. Koppolu, and F. H. Sarkar, “Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells,” Oncogene, vol. 20, no. 23, pp. 2927–2936, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Li and F. H. Sarkar, “Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway,” Clinical Cancer Research, vol. 8, no. 7, pp. 2369–2377, 2002. View at Google Scholar · View at Scopus
  121. Y. Li, S. R. Chinni, and F. H. Sarkar, “Selective growth regulatory and pro-apoptotic effects of DIM is mediated by Akt and NF-kappaB pathways in prostate cancer cells,” Frontiers in Bioscience, vol. 10, no. 1, pp. 236–243, 2005. View at Google Scholar · View at Scopus
  122. M. C. Brahimi-Horn and J. Pouysségur, “The hypoxia-inducible factor and tumor progression along the angiogenic pathway,” International Review of Cytology, vol. 242, pp. 157–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. M. A. Esteban and P. H. Maxwell, “HIF, a missing link between metabolism and cancer,” Nature Medicine, vol. 11, no. 10, pp. 1047–1048, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. G. L. Semenza, “Targeting HIF-1 for cancer therapy,” Nature Reviews Cancer, vol. 3, no. 10, pp. 721–732, 2003. View at Google Scholar · View at Scopus
  125. A. L. Harris, “Hypoxia—a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp. 38–47, 2002. View at Google Scholar · View at Scopus
  126. M. López-Lázaro, “HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?” FASEB Journal, vol. 20, no. 7, pp. 828–832, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. G. L. Semenza, “Development of novel therapeutic strategies that target HIF-1,” Expert Opinion on Therapeutic Targets, vol. 10, no. 2, pp. 267–280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Giaccia, B. G. Siim, and R. S. Johnson, “HIF-1 as a target for drug development,” Nature Reviews Drug Discovery, vol. 2, no. 10, pp. 803–811, 2003. View at Google Scholar · View at Scopus
  129. D. G. Nagle and Y. D. Zhou, “Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1),” Current Drug Targets, vol. 7, no. 3, pp. 355–369, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. E. J. Yeo, Y. S. Chun, and J. W. Park, “New anticancer strategies targeting HIF-1,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1061–1069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. H. Zhong, A. M. De Marzo, E. Laughner et al., “Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases,” Cancer Research, vol. 59, no. 22, pp. 5830–5835, 1999. View at Google Scholar · View at Scopus
  132. C. J. Schofield and P. J. Ratcliffe, “Oxygen sensing by HIF hydroxylases,” Nature Reviews Molecular Cell Biology, vol. 5, no. 5, pp. 343–354, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Shou, S. Massarweh, C. K. Osborne et al., “Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 926–935, 2004. View at Google Scholar · View at Scopus
  134. W. H. Mondesire, W. Jian, H. Zhang et al., “Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells,” Clinical Cancer Research, vol. 10, no. 20, pp. 7031–7042, 2004. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Knuefermann, Y. Lu, B. Liu et al., “HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells,” Oncogene, vol. 22, no. 21, pp. 3205–3212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Nahta and F. J. Esteva, “HER2 therapy: molecular mechanisms of trastuzumab resistance,” Breast Cancer Research, vol. 8, no. 6, article 215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. T. T. Junttila, R. W. Akita, K. Parsons et al., “Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941,” Cancer Cell, vol. 15, no. 5, pp. 429–440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. E. Raymond, J. Alexandre, S. Faivre et al., “Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2336–2347, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Yu, L. Toral-Barza, C. Discafani et al., “mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer,” Endocrine-Related Cancer, vol. 8, no. 3, pp. 249–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Li, J. Lin, X. Wang et al., “Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer,” Breast Cancer Research and Treatment. In press. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Liu, A. Howes, J. Lesperance et al., “Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer,” Cancer Research, vol. 65, no. 12, pp. 5325–5336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  142. R. Namba, L. J. T. Young, C. K. Abbey et al., “Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ,” Clinical Cancer Research, vol. 12, no. 8, pp. 2613–2621, 2006. View at Publisher · View at Google Scholar · View at Scopus